{"id":"https://openalex.org/W2131983256","doi":"https://doi.org/10.1111/bcp.12377","title":"Pitavastatin is a more sensitive and selective organic anion\u2010transporting polypeptide 1B clinical probe than rosuvastatin","display_name":"Pitavastatin is a more sensitive and selective organic anion\u2010transporting polypeptide 1B clinical probe than rosuvastatin","alternate_titles":[],"publication_year":2014,"publication_date":"2014-08-21","ids":{"openalex":"https://openalex.org/W2131983256","doi":"https://doi.org/10.1111/bcp.12377","mag":"2131983256","pmid":"https://pubmed.ncbi.nlm.nih.gov/24617605","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4243909"},"language":"en","primary_location":{"id":"doi:10.1111/bcp.12377","doi":"https://doi.org/10.1111/bcp.12377","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.12377","pdf_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.12377","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2131983256"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.12377","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017950194","display_name":"Thomayant Prueksaritanont","orcid":"https://orcid.org/0000-0001-6810-9692","observed_orcids":["https://orcid.org/0000-0001-6810-9692"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Thomayant Prueksaritanont","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082048814","display_name":"Xiaoyan Chu","orcid":"https://orcid.org/0000-0001-7223-9000","observed_orcids":["https://orcid.org/0000-0001-7223-9000"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Xiaoyan Chu","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064222916","display_name":"Raymond Evers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Raymond Evers","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050905161","display_name":"Stephanie Olsen Klopfer","orcid":"https://orcid.org/0009-0007-5247-3044","observed_orcids":["https://orcid.org/0009-0007-5247-3044"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stephanie O. Klopfer","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084630027","display_name":"Luzelena Caro","orcid":"https://orcid.org/0000-0003-2275-8771","observed_orcids":["https://orcid.org/0000-0003-2275-8771"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Luzelena Caro","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079794570","display_name":"Prajakti A. Kothare","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Prajakti A. Kothare","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022629870","display_name":"Cynthia Dempsey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Cynthia Dempsey","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038336871","display_name":"Scott Rasmussen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Scott Rasmussen","raw_affiliation_strings":["Quintiles; Durham NC USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quintiles; Durham NC USA","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012642289","display_name":"Robert Houle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert Houle","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110277830","display_name":"Grace Hoyee Chan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Grace Chan","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103203349","display_name":"Xiaoxin Cai","orcid":"https://orcid.org/0000-0002-2647-1527","observed_orcids":["https://orcid.org/0000-0002-2647-1527"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Xiaoxin Cai","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023483241","display_name":"Robert J. Valesky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert Valesky","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013726991","display_name":"Iain P. Fraser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Iain P. Fraser","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5011021512","display_name":"Selwyn Aubrey Stoch","orcid":"https://orcid.org/0000-0001-5620-7092","observed_orcids":["https://orcid.org/0000-0001-5620-7092"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"S. Aubrey Stoch","raw_affiliation_strings":["Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories Merck & Co., Inc. Whitehouse Station NJ USA","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5011021512"],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":7.7264,"has_fulltext":true,"cited_by_count":181,"citation_normalized_percentile":{"value":0.98540426,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"78","issue":"3","first_page":"587","last_page":"598"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.008200000040233135,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11908","display_name":"Protein Interaction Studies and Fluorescence Analysis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pitavastatin","display_name":"pitavastatin","score":0.9829999804496765},{"id":"https://openalex.org/keywords/rosuvastatin","display_name":"rosuvastatin","score":1.0},{"id":"https://openalex.org/keywords/oatp1b","display_name":"OATP1B","score":0.9279999732971191},{"id":"https://openalex.org/keywords/organic-anion-transporting-polypeptides","display_name":"organic anion transporting polypeptides","score":0.746999979019165},{"id":"https://openalex.org/keywords/rifampicin","display_name":"rifampicin","score":0.8790000081062317},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.5350000262260437},{"id":"https://openalex.org/keywords/probe-substrates","display_name":"probe substrates","score":0.5889999866485596},{"id":"https://openalex.org/keywords/oatp1b1","display_name":"OATP1B1","score":0.902999997138977},{"id":"https://openalex.org/keywords/oatp1b3","display_name":"OATP1B3","score":0.9990000128746033},{"id":"https://openalex.org/keywords/abcg2","display_name":"ABCG2","score":0.8119999766349792},{"id":"https://openalex.org/keywords/mdr2","display_name":"MDR2","score":0.7820000052452087},{"id":"https://openalex.org/keywords/oat3","display_name":"OAT3","score":0.8080000281333923},{"id":"https://openalex.org/keywords/statin-pharmacokinetics","display_name":"statin pharmacokinetics","score":0.5799999833106995}],"concepts":[{"id":"https://openalex.org/C2776692505","wikidata":"https://www.wikidata.org/wiki/Q412677","display_name":"Pitavastatin","level":3,"score":0.9850529432296753},{"id":"https://openalex.org/C2780499067","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin","level":2,"score":0.9403513669967651},{"id":"https://openalex.org/C2776678969","wikidata":"https://www.wikidata.org/wiki/Q28209167","display_name":"Organic anion-transporting polypeptide","level":4,"score":0.7496845126152039},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7191036343574524},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.62476646900177},{"id":"https://openalex.org/C2778607973","wikidata":"https://www.wikidata.org/wiki/Q422652","display_name":"Rifampicin","level":3,"score":0.6003860235214233},{"id":"https://openalex.org/C123584848","wikidata":"https://www.wikidata.org/wiki/Q18034026","display_name":"Organic anion transporter 1","level":4,"score":0.5867175459861755},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5631912350654602},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4171587824821472},{"id":"https://openalex.org/C2908737378","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin Calcium","level":3,"score":0.4151046872138977},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.346434623003006},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17865929007530212},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.117770254611969},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068718","descriptor_name":"Rosuvastatin Calcium","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000074542","descriptor_name":"Solute Carrier Organic Anion Transporter Family Member 1B3","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005464","descriptor_name":"Fluorobenzenes","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D012293","descriptor_name":"Rifampin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D012293","descriptor_name":"Rifampin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D022781","descriptor_name":"Hepatocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D022781","descriptor_name":"Hepatocytes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D027361","descriptor_name":"Organic Anion Transporters","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D027361","descriptor_name":"Organic Anion Transporters","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D027381","descriptor_name":"Liver-Specific Organic Anion Transporter 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D029362","descriptor_name":"Organic Anion Transporters, Sodium-Independent","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D029362","descriptor_name":"Organic Anion Transporters, Sodium-Independent","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061605","descriptor_name":"Administration, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/bcp.12377","doi":"https://doi.org/10.1111/bcp.12377","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.12377","pdf_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.12377","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4243909","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4243909/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:24617605","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24617605","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Comparative Study"}],"best_oa_location":{"id":"doi:10.1111/bcp.12377","doi":"https://doi.org/10.1111/bcp.12377","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.12377","pdf_url":"https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.12377","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2131983256.pdf","grobid_xml":"https://content.openalex.org/works/W2131983256.grobid-xml"},"referenced_works_count":40,"referenced_works":["https://openalex.org/W1578075719","https://openalex.org/W1868407335","https://openalex.org/W1973508181","https://openalex.org/W1973810935","https://openalex.org/W1976696095","https://openalex.org/W1978116407","https://openalex.org/W1985330287","https://openalex.org/W2000220014","https://openalex.org/W2005998697","https://openalex.org/W2007465373","https://openalex.org/W2010448327","https://openalex.org/W2011163792","https://openalex.org/W2022663382","https://openalex.org/W2028211844","https://openalex.org/W2028444358","https://openalex.org/W2030021013","https://openalex.org/W2032622924","https://openalex.org/W2034947261","https://openalex.org/W2036741913","https://openalex.org/W2039299577","https://openalex.org/W2043432548","https://openalex.org/W2044906812","https://openalex.org/W2064703458","https://openalex.org/W2082627462","https://openalex.org/W2095010499","https://openalex.org/W2095930613","https://openalex.org/W2102417187","https://openalex.org/W2104270120","https://openalex.org/W2110287784","https://openalex.org/W2130389909","https://openalex.org/W2131020156","https://openalex.org/W2131138924","https://openalex.org/W2136918221","https://openalex.org/W2137332312","https://openalex.org/W2141941946","https://openalex.org/W2143945489","https://openalex.org/W2148587422","https://openalex.org/W2159908530","https://openalex.org/W2165323828","https://openalex.org/W2171070365"],"related_works":["https://openalex.org/W2799486834","https://openalex.org/W2797428118","https://openalex.org/W2942626091","https://openalex.org/W4236998064","https://openalex.org/W2804785564","https://openalex.org/W2131138924","https://openalex.org/W4408515180","https://openalex.org/W2169248001","https://openalex.org/W2895827580","https://openalex.org/W4408129228"],"abstract_inverted_index":{"AIMS:":[0],"Rosuvastatin":[1],"and":[2,24,49,124,162,166,168,174,189,195,217,219,228],"pitavastatin":[3,102,165,212],"have":[4],"been":[5],"proposed":[6],"as":[7,42],"probe":[8,224],"substrates":[9],"for":[10,146,164,170],"the":[11,54,151,156],"organic":[12,203],"anion-transporting":[13],"polypeptide":[14],"(OATP)":[15],"1B,":[16],"but":[17,200],"clinical":[18,32,74,222],"data":[19],"on":[20,69],"their":[21,39],"relative":[22,40],"sensitivity":[23],"selectivity":[25],"to":[26,37,91],"OATP1B":[27,43,55,223,240],"inhibitors":[28],"are":[29],"lacking.":[30],"A":[31],"study":[33,75],"was":[34,184],"therefore":[35],"conducted":[36],"determine":[38],"suitability":[41],"probes":[44],"using":[45,122],"single":[46,94,231],"oral":[47,95],"(PO)":[48],"intravenous":[50],"(IV)":[51],"doses":[52],"of":[53,65,77,81,97,133,150,187,202,234],"inhibitor":[56,186,241],"rifampicin,":[57,176],"accompanied":[58],"by":[59],"a":[60,93,214,230,237,243],"comprehensive":[61],"in":[62,116,153],"vitro":[63,117,179],"assessment":[64],"rifampicin":[66,109,144,183,235],"inhibitory":[67],"potential":[68],"statin":[70],"transporters.":[71],"METHODS:":[72],"The":[73,115,148,208],"comprised":[76],"two":[78],"separate":[79],"panels":[80],"eight":[82],"healthy":[83],"subjects.":[84],"In":[85,178],"each":[86],"panel,":[87],"subjects":[88],"were":[89,120,160],"randomized":[90],"receive":[92],"dose":[96,233],"rosuvastatin":[98],"(5":[99],"mg)":[100,104,111],"or":[101,113],"(1":[103],"administered":[105],"alone,":[106],"concomitantly":[107],"with":[108,136],"(600":[110],"PO":[112,141,173,244],"IV.":[114],"transporter":[118,205],"studies":[119,180],"performed":[121],"hepatocytes":[123],"recombinant":[125],"expression":[126],"systems.":[127],"RESULTS:":[128],"Rifampicin":[129],"markedly":[130],"increased":[131],"exposures":[132],"both":[134],"statins,":[135],"greater":[137],"differential":[138],"increases":[139,152],"after":[140,172],"vs.":[142],"IV":[143,175,232],"only":[145],"rosuvastatin.":[147],"magnitudes":[149],"area":[154],"under":[155],"plasma":[157],"concentration-time":[158],"curve":[159],"5.7-":[161],"7.6-fold":[163],"4.4-":[167],"3.3-fold":[169],"rosuvastatin,":[171,227],"respectively.":[177],"showed":[181],"that":[182,211,229],"an":[185],"OATP1B1":[188],"OATP1B3,":[190],"breast":[191],"cancer":[192],"resistance":[193,197],"protein":[194,198],"multidrug":[196],"2,":[199],"not":[201],"anion":[204],"3.":[206],"CONCLUSIONS:":[207],"results":[209],"indicate":[210],"is":[213,236],"more":[215,238],"sensitive":[216],"selective":[218,239],"thus":[220],"preferred":[221],"substrate":[225],"than":[226,242],"dose.":[245]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2131983256","counts_by_year":[{"year":2026,"cited_by_count":10},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":14},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":11},{"year":2021,"cited_by_count":17},{"year":2020,"cited_by_count":19},{"year":2019,"cited_by_count":18},{"year":2018,"cited_by_count":28},{"year":2017,"cited_by_count":20},{"year":2016,"cited_by_count":18},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
